Literature DB >> 8530816

Tamoxifen-associated steatohepatitis--report of three cases.

H C Pinto1, A Baptista, M E Camilo, E B de Costa, A Valente, M C de Moura.   

Abstract

The authors describe three cases of tamoxifen-associated steatohepatitis, which resulted from a daily dosage of 20 mg used as the adjuvant treatment of breast carcinoma. Liver tests became normal after discontinuation of tamoxifen.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8530816     DOI： 10.1016/0168-8278(95)80316-5

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


  13 in total

Review 1.  Dose adaptation of antineoplastic drugs in patients with liver disease.

Authors:  Lydia Tchambaz; Chantal Schlatter; Max Jakob; Anita Krähenbühl; Peter Wolf; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Diffuse desmoplastic metastatic breast cancer simulating cirrhosis with severe portal hypertension: a case of "pseudocirrhosis".

Authors:  David A Sass; Kenneth Clark; Dana Grzybicki; Mordechai Rabinovitz; Thomas A Shaw-Stiffel
Journal:  Dig Dis Sci       Date:  2007-03       Impact factor: 3.199

3.  Effect of Sargassum polycystum (Phaeophyceae)-sulphated polysaccharide extract against acetaminophen-induced hyperlipidemia during toxic hepatitis in experimental rats.

Authors:  Hanumantha Rao Balaji Raghavendran; Arumugam Sathivel; Thiruvengadam Devaki
Journal:  Mol Cell Biochem       Date:  2005-08       Impact factor: 3.396

4.  Integrating Drug's Mode of Action into Quantitative Structure-Activity Relationships for Improved Prediction of Drug-Induced Liver Injury.

Authors:  Leihong Wu; Zhichao Liu; Scott Auerbach; Ruili Huang; Minjun Chen; Kristin McEuen; Joshua Xu; Hong Fang; Weida Tong
Journal:  J Chem Inf Model       Date:  2017-04-10       Impact factor: 4.956

5.  Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice.

Authors:  Y Nemoto; K Toda; M Ono; K Fujikawa-Adachi; T Saibara; S Onishi; H Enzan; T Okada; Y Shizuta
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

6.  Fatty metamorphosis of the liver in patients with breast cancer: possible associated factors.

Authors:  Cheng-Hsin Chu; Shee-Chan Lin; Shou-Chuan Shih; Chin-Roa Kao; Sun-Yen Chou
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

7.  Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient (Ar-/-) mice.

Authors:  Tetsu Egawa; Katsumi Toda; Yoshihisa Nemoto; Masafumi Ono; Naoaki Akisaw; Toshiji Saibara; Yoshihiro Hayashi; Makoto Hiroi; Hideaki Enzan; Saburo Onishi
Journal:  Lipids       Date:  2003-05       Impact factor: 1.880

8.  A case-control study of non-alcoholic fatty liver disease in breast cancer.

Authors:  Ahmet Bilici; Mustafa Ozguroglu; Ismail Mihmanli; Hande Turna; Ibrahim Adaletli
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

9.  Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients.

Authors:  H C Pinto; A Baptista; M E Camilo; A Valente; A Saragoça; M C de Moura
Journal:  Dig Dis Sci       Date:  1996-01       Impact factor: 3.199

10.  Cirrhosis-like radiological pattern in patients with breast cancer.

Authors:  César Gómez Raposo; Andrés Redondo Sánchez; Félix Guerra-Gutiérrez; Beatriz Castelo Fernández; Silvia Gómez Senent; Enrique Espinosa Arranz; Beatriz Martínez Martínez; Pilar Zamora Auñón; Manuel González Barón
Journal:  Clin Transl Oncol       Date:  2008-02       Impact factor: 3.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.